European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)PRNewsWire • 04/18/24
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesPRNewsWire • 04/10/24
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin OpportunityPRNewsWire • 03/27/24
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLPRNewsWire • 03/27/24
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialPRNewsWire • 03/25/24
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and WebcastPRNewsWire • 03/20/24
Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3PRNewsWire • 01/24/24
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-MarketPRNewsWire • 12/21/23
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual MeetingPRNewsWire • 12/11/23
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 MonthsPRNewsWire • 11/13/23
Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and WebcastPRNewsWire • 11/07/23
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung MetastasesPRNewsWire • 11/06/23
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)PRNewsWire • 10/02/23
Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)PRNewsWire • 09/21/23